You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 28, 2025

Drug Price Trends for NDC 72603-0168


✉ Email this page to a colleague

« Back to Dashboard


Average Pharmacy Cost for 72603-0168

Drug NameNDCPrice/Unit ($)UnitDate
PROCHLORPERAZINE 5 MG TABLET 72603-0168-01 0.16620 EACH 2025-07-23
PROCHLORPERAZINE 5 MG TABLET 72603-0168-01 0.16062 EACH 2025-06-18
PROCHLORPERAZINE 5 MG TABLET 72603-0168-01 0.15306 EACH 2025-05-21
PROCHLORPERAZINE 5 MG TABLET 72603-0168-01 0.15867 EACH 2025-04-23
PROCHLORPERAZINE 5 MG TABLET 72603-0168-01 0.16884 EACH 2025-03-19
PROCHLORPERAZINE 5 MG TABLET 72603-0168-01 0.16389 EACH 2025-02-19
PROCHLORPERAZINE 5 MG TABLET 72603-0168-01 0.15185 EACH 2025-01-22
>Drug Name>NDC>Price/Unit ($)>Unit>Date
Showing 1 to 7 of 7 entries

Best Wholesale Price for NDC 72603-0168

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions
Drug NameVendorNDCCountPrice ($)Price/Unit ($)DatesPrice Type
No data available in table
>Drug Name>Vendor>NDC>Count>Price ($)>Price/Unit ($)>Dates>Price Type
Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies
Showing 0 to 0 of 0 entries

Market Analysis and Price Projections for the Drug NDC: 72603-161

Last updated: July 27, 2025

Introduction

The pharmaceutical market is complex and heavily influenced by regulatory changes, market demand, and competitive dynamics. This analysis focuses on the drug identified by the National Drug Code (NDC) 72603-161, although specific details about this NDC are not provided in the sources. We will discuss general trends and factors that could impact the pricing and market analysis of drugs with similar characteristics.

Drug Pricing Trends

Drug prices have been a significant concern in the healthcare sector, particularly for Medicare and other healthcare payers. Recent data shows that many prescription drugs have experienced substantial price increases over the past few years.

  • Price Increases: Between 2018 and 2023, many drugs saw list price increases ranging from 20% to 55%[2].
  • Affordability Challenges: High prescription drug prices create affordability challenges for patients, healthcare payers, and taxpayers. The Medicare Drug Price Negotiation Program aims to address these challenges by negotiating prices for high-expenditure, single-source drugs without generic or biosimilar competition[2].

Medicare Drug Price Negotiation Program

This program is a crucial factor in the pricing dynamics of certain drugs, including those selected for negotiation under Medicare Part D.

  • Selected Drugs: The first cycle of negotiation includes drugs like Eliquis, Jardiance, Xarelto, Januvia, Farxiga, Entresto, Enbrel, Imbruvica, Stelara, and NovoLog/Fiasp. These drugs treat conditions such as cardiovascular disease, diabetes, and cancer, affecting millions of Medicare enrollees[2].
  • Negotiated Prices: The negotiated prices, known as Maximum Fair Prices (MFP), result in discounts ranging from 38% to 79% compared to list prices. For example, the negotiated price for a 30-day equivalent supply of these drugs is significantly lower than their list prices[2].

Impact on Market Prices

The negotiation of drug prices under Medicare Part D can have broader implications for the market.

  • Market Discounts: The significant discounts achieved through negotiation can set a precedent for other payers and may influence the overall market prices of these drugs. This could lead to lower prices across different healthcare systems and insurance plans[2].
  • Manufacturer Response: Drug manufacturers may adjust their pricing strategies in response to these negotiations. This could include revising list prices or offering more competitive pricing to maintain market share[2].

Methodology for Identifying Drugs for Affordability Review

Regulatory bodies use specific methodologies to identify drugs that require affordability reviews.

  • Price Increase Thresholds: Drugs with price increases of 15% or more in a 12-month period or a 50% cumulative increase over three years are typically flagged for review[3].
  • Cost Thresholds: Drugs with high total costs, such as those exceeding $60,000 for a course of treatment, are also subject to review[3].

Specific Drug Analysis

While the specific details of NDC 72603-161 are not provided, we can infer some general points based on similar drugs.

  • Category and Distribution: If the drug falls under a category with high demand and limited competition, it may be subject to higher pricing. The distribution channels and marketing strategies can also impact its market price[1][4].

Price Projections

Given the current trends and regulatory changes:

  • Short-Term Projections: For drugs selected for negotiation under Medicare Part D, prices are expected to decrease significantly due to the negotiated Maximum Fair Prices. This could lead to a ripple effect in the market, potentially reducing prices for similar drugs[2].
  • Long-Term Projections: Over the long term, the impact of these negotiations and the broader market dynamics will continue to shape drug prices. Manufacturers may need to adjust their pricing strategies to remain competitive, which could lead to more stable or reduced prices[2].

Industry Expert Insights

Industry experts often highlight the complexities and challenges in drug pricing.

  • "The negotiation of drug prices under Medicare Part D is a significant step towards making prescription drugs more affordable for patients and reducing the financial burden on healthcare systems," said a healthcare policy analyst. This reflects the broader sentiment that such negotiations can have a positive impact on affordability and access to essential medications[2].

Statistics and Examples

  • Medicare Part D Spending: The 10 drugs selected for the first cycle of negotiation accounted for $56.2 billion in total Part D gross covered prescription drug costs in 2023, which is about 20% of the total Part D gross covered prescription drug costs for that year[2].
  • Price Increases: For example, the list price of Enbrel increased by 55% between 2018 and 2023, while NovoLog/Fiasp saw a slight decline of 1% over the same period[2].

Key Takeaways

  • Regulatory Impact: Negotiations under Medicare Part D can significantly reduce drug prices.
  • Market Dynamics: Price increases and affordability reviews are critical factors in shaping drug prices.
  • Manufacturer Strategies: Drug manufacturers must adapt to changing market conditions and regulatory requirements.
  • Patient Affordability: Lower prices can improve patient access to essential medications.

FAQs

Q: What is the Medicare Drug Price Negotiation Program? A: The Medicare Drug Price Negotiation Program is an initiative to negotiate prices for high-expenditure, single-source drugs without generic or biosimilar competition under Medicare Part D.

Q: How do negotiated prices under Medicare Part D affect the market? A: Negotiated prices can lead to significant discounts, influencing the overall market prices of these drugs and potentially setting a precedent for other payers.

Q: What criteria are used to identify drugs for affordability reviews? A: Drugs with price increases of 15% or more in a 12-month period or a 50% cumulative increase over three years are typically flagged for review.

Q: How do regulatory changes impact drug pricing? A: Regulatory changes, such as those under the Medicare Drug Price Negotiation Program, can significantly reduce drug prices and influence market dynamics.

Q: What is the expected long-term impact on drug prices? A: Over the long term, prices may stabilize or reduce as manufacturers adjust their pricing strategies to remain competitive in a market influenced by negotiated prices.

Sources

  1. FDA.report - NDC 72603-161
  2. ASPE - HHS.gov - Medicare Drug Price Negotiation Program
  3. HCA.WA.GOV - Methodology for Identifying Drugs for Affordability Review
  4. DailyMed - METOPROLOL SUCCINATE tablet, extended release
  5. DFR.Oregon.Gov - Prescription Drug Price Transparency Results and Recommendations

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.